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The hypothesis that infectious agents
are a risk factor for atherosclerosis has
implicated multiple viral and bacte-
rial pathogens in contributing either
directly or indirectly to disease progres-
sion (Rosenfeld and Campbell, 2011). One
of the most vigorously studied organ-
isms has been Chlamydia pneumoniae,
which has been associated with cardio-
vascular disease by seroepidemiological
studies, detection of the organism by mul-
tiple methods in atherosclerotic tissue,
and experimental studies demonstrat-
ing biological plausibility. Significantly,
C. pneumoniae accelerates lesion pro-
gression in mouse and rabbit models of
atherosclerosis (Muhlestein et al., 1998;
Hu et al., 1999; Moazed et al., 1999; Fong,
2000; Blessing et al., 2001). Early small
clinical trials determined whether treat-
ment with macrolides (Azithromycin,
Roxithromycin, and Clarithromycin)
would be efficacious in secondary pre-
vention of coronary heart disease. These
studies yielded mixed results and had
several limitations including the small
numbers of patients and short dura-
tion of treatment and follow-up period
(Grayston, 2003). However, half of them
demonstrated some beneficial effects,
which provided enthusiasm for the poten-
tial of antibiotic intervention in coronary
artery disease. There have since been four
large clinical trials collectively enrolling
over 20,000 patients with stable coro-
nary artery disease (WIZARD, ACES,
and CLARICOR) or acute coronary syn-
drome (PROVE-IT–TIMI) (O’Connor
et al., 2003; Cannon et al., 2005; Grayston
et al., 2005; Jespersen et al., 2006). As there
were short term beneficial effects in the
WIZARD trial following a 3 month course
of Azithromycin, two subsequent studies
addressed whether longer term treatment
would be efficacious in reducing coro-
nary events. In the ACES study, patients
were treated with Azithromycin for 1 year
and followed for 46.8 months (Grayston
et al., 2005). The PROVE IT-TIMI trial
treated with gatifloxacin for a mean dura-
tion of 2 years (Cannon et al., 2005).
Overall, none of these well-designed tri-
als demonstrated any long term benefit
of antibiotic treatment. Furthermore, two
large scale trials subsequently found that
treatment with either roxithromycin or
rifalizil (PROVIDENCE-1) had no ben-
eficial effects in patients with peripheral
artery disease (Joensen et al., 2008; Jaff
et al., 2009). Cumulatively, these trials
clearly demonstrated that anti-chlamydial
antibiotics should not be recommended
for treatment of patients with coronary
heart disease or peripheral artery disease.
Prior to the completion of the PROVE-IT
and ACES trials, Grayston commented
that if the trials demonstrated a ben-
eficial effect of antibiotics, this would
provide additional evidence for a role of
C. pneumoniae in pathogenesis, but would
not prove causality (Grayston, 2003).
Alternatively, he predicted that negative
results would mostly likely dampen inter-
est in the association of C. pneumoniae
and atherosclerosis, but noted that failure
of the clinical trials would not rule out a
pathogenic role (Grayston, 2003). Indeed,
the negative outcome led some to con-
clude that this proved that C. pneumoniae
did not play a role in the pathogenesis
of atherosclerosis (Danesh, 2005) and
diminished interest in infectious agents
as contributing factors for cardiovascular
disease (Epstein et al., 2009).
However, other investigators have
underscored several factors that war-
rant critical evaluation before dismissing
C. pneumoniae as a contributor to
atherosclerotic processes (Anderson,
2005; Taylor-Robinson and Boman, 2005;
Deniset and Pierce, 2010; Muhlestein,
2011; Rosenfeld and Campbell, 2011).
First, treatment was given to patients
with “end stage of disease” that is likely
not modifiable. By analogy, antibiotic
treatment is not effective in individuals
in which inflammation resulting from
chronic C. trachomatis infection of the
upper genital tract or eye has led to the
fibrosis and scarring observed in tubal
factor infertility and trachoma, respec-
tively. Whether antibiotics would be
efficacious in treatment of patients with
early atherosclerosis has not been deter-
mined as such studies would be difficult
to design and execute. Second, it is pos-
sible that antibiotic treatment might be
ineffective due to pathogen burden as
viruses or other bacteria contributing to
atherosclerotic processes may not be sus-
ceptible to the chosen antibiotics (Epstein
et al., 2009; Rosenfeld and Campbell,
2011). Third, the patients in the large
scale trials had advanced atherosclero-
sis and the events being measured were
likely due to plaque destabilization and
rupture, events that may be independent
of plaque progression due to infection.
Fourth, a single antibiotic was used in
the trials and it is possible that treatment
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with a combination of antibiotics might
be more effective as shown for patients
with chronic Chlamydia-induced reactive
arthritis (Carter et al., 2010). Last, and
the focus of this opinion, is the ability of
chlamydiae to establish persistent/chronic
infection and the difficulty in treating such
infections (Beatty et al., 1994; Grayston,
2003). Chlamydiae undergo a develop-
mental cycle in which the elementary
body, an infectious but metabolically inac-
tive form, is not susceptible to antibiotics.
The reticulate body, the intracellular repli-
cating form, can establish persistence, a
state in which the developmental cycle is
arrested rendering the organism refrac-
tory to antibiotics. In a continuous cell
culture model of C. pneumoniae infec-
tion thought to more accurately mimic
in vivo conditions, a mixture of develop-
mental forms, including aberrant forms
characteristic of persistent organisms,
are observed. In this model, prolonged
treatment with antibiotics including
azithromycin and clarithromycin failed to
eliminate infection (Kutlin et al., 2002a,b).
It was also demonstrated in infected
monocytes in vitro and monocytes iso-
lated from patients undergoing treatment
with azithromycin for coronary artery
disease that infection was recalcitrant
to antibiotic treatment (Gieffers et al.,
2001). In addition, various antibiotics
can induce chlamydial persistence in cell
culture, including azithromycin (Beatty
et al., 1994; Gieffers et al., 2004; Wyrick
and Knight, 2004). Recently, amoxicillin
has been shown to result in the induc-
tion of reversible persistent Chlamydia
muridarum infection in a mouse model of
genital tract infection (Phillips Campbell,
2012). The ability of C. pneumoniae to
establish persistent infection in vivo has
been experimentally validated in a mouse
model of lung infection (Malinverni et al.,
1995a; Laitinen et al., 1996). At times
post-infection in which the organism can
no longer be cultured from the lungs
(but pathology persists and the organ-
ism can be detected by PCR), treatment
with cortisone acetate results in reactiva-
tion of infection and the ability to culture
organisms. Importantly, in animal mod-
els, the organism is frequently detected by
PCR or immunohistochemistry follow-
ing treatment with antibiotics. In acute
lung infection, treatment of mice with a
single dose of azithromycin or doxycy-
cline resulted in an inability to culture the
organism compared to untreated controls.
However, 77 and 25% of the culture-
negative lungs were positive by PCR,
respectively, and no differences in lung
histopathology were noted (Malinverni
et al., 1995b). This study suggests that
infection was not eradicated and raises the
question as to whether persistent infec-
tion was induced earlier in the course
of infection as a result of treatment. In
hyperlipidemic apoE-deficient mice, fol-
lowing either a single or three intranasal
inoculations starting at 8 weeks of age,
C. pneumoniae could be cultured from the
aorta for 1–2 weeks after the first inocula-
tion, although the aorta remained PCR
positive up to 28 weeks of age. These
results suggest that the organism can
establish persistent infection of the aorta.
This was also supported by immunohis-
tochemical detection of the organism in
foam cells in 24 week old mice (Moazed
et al., 1997, 1999). Significantly, two inde-
pendent studies were done in this model in
which mice were infected and treated with
azithromycin at a dose that is comparable
to that given to humans for chlamydial
respiratory infection (Rothstein et al.,
2001; Blessing et al., 2005). In the first
study, mice were infected twice, 1 week
apart, and treated with azithromycin 2
weeks after each inoculation (Rothstein
et al., 2001). In the other study, mice were
infectedmice three times, 1 week apart and
received a 6 week course of azithromycin.
In the latter study, mice were treated on
days 3, 4, and 5 after the third infec-
tion and once a week for 5 subsequent
weeks (Blessing et al., 2005). Neither treat-
ment regimen had any beneficial effects on
C. pneumoniae accelerated atherosclerosis.
In the first study, at the endpoint of 26
weeks of age (12 weeks after the second
inoculation), C. pneumoniae DNA was
identified in lung, heart and aorta in 50%
of both treated and untreated mice. An
earlier study in New Zealand White rab-
bits treated with azithromycin for 7 weeks
immediately following the third infection,
demonstrated a decrease in C. pneumoniae
accelerated intimal thickening. However,
C. pneumoniae antigen was still detected
in 3/10 treated rabbits in comparison to
2/9 untreated animals (Muhlestein et al.,
1998). Fong et al. found that the time
of treatment with antibiotic was key to
mitigating the effect of C. pneumoniae
infection on atherosclerosis development
in rabbits. Early treatment of acute infec-
tion with clarithromycin, resulted in
reduced effects; however, with delayed
treatment there was not a statistically
significant reduction in the detection of
organism in atherosclerotic tissues in com-
parison to untreated rabbits. These studies
provide further evidence that C. pneu-
moniae establishes persistent infection
in vivo, which is refractory to antibiotic
intervention.
A large number of studies from
independent laboratories demonstrated
the presence of the organism within
human atherosclerotic tissue by detec-
tion of C. pneumoniae antigen and/or
DNA (Campbell and Kuo, 2004; Taylor-
Robinson and Boman, 2005). However,
isolation of the organism has been rare
(Ramirez, 1996; Jackson et al., 1997), sug-
gesting that C. pneumoniae establishes
persistent infection in the vasculature.
Unfortunately, there are no clearly defined
markers of persistent infection in humans.
To identify such markers, Borel and
her colleagues applied tissue microar-
ray (TMA) technology coupled with
immunohistochemistry using antibod-
ies prepared against proteins that were
differentially expressed in vitro in a
gamma-interferon induced model of
C. pneumoniae persistence (Molestina
et al., 2002; Mukhopadhyay et al., 2006)
and examined archived tissues from
patients undergoing heart transplanta-
tion. An advantage of this tissue set was
that C. pneumoniae had been detected
in 7 of 12 patients by various methods
and the organism was cultured from 1
of these patients (Ramirez, 1996). By
TMA analysis, heart tissue from 10 of
12 patients were positively stained with
antibodies against proteins upregulated in
the persistent state (GroEL and GroES)
and all were negative when stained with
an antibody against a downregulated pro-
tein (Borel et al., 2006). Using a subset
of these specimens, “aberrant” forms
were visualized by transmission elec-
tron microscopy (TEM) and immunogold
labeling with antibodies against GroEL
and GroES. These forms were confirmed
as C. pneumoniae by double labeling with
other C. pneumoniae specific antibodies
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providing evidence of persistent infection
in atheromas (Borel et al., 2008). A recent
prospective study stained coronary heart
tissue from patients undergoing heart
transplants with a panel of antibodies
against C. pneumoniae proteins upregu-
lated in “aberrant” forms and detected
antigen in 11 of 13 patients, supporting
the notion that these antigens may serve
as a marker of persistent infection (Borel
et al., 2012). However, none of the tissues
were PCR positive, nor was any ultrastruc-
tural evidence of the organism observed
by TEM (Borel et al., 2012). The latter may
reflect sampling size and the limited area
of the atheroma that can reasonably be
analyzed by this method. In our experi-
ence with immunohistochemical staining,
detection of the organism in atheroscle-
rotic lesions is localized and analysis of
sequential sections can yield disparate
results. The negative PCR results are more
difficult to interpret when compared with
the studies of archived tissue, although
sampling may again play a role.
In conclusion, the negative outcome of
the antibiotic trials should not result in
dismissing substantive evidence support-
ing C. pneumoniae infection as a potential
contributor to atherosclerotic processes
without rigorous investigation of other
factors that may alternatively explain the
lack of benefits (or not). One of these is
the ability of chlamydiae to establish per-
sistent infection, a state that is refractory
to antibiotic treatment. The availability
of mouse models of persistent chlamydial
infection should be exploited to specif-
ically address whether: (1) antibiotics
induce persistent C. pneumoniae infection
in the vasculature; (2) persistent infec-
tion of the vasculature can be reactivated
by immunosuppression; (3) the absence
of an effect of antibiotic intervention on
C. pneumoniae accelerated atherosclerosis
is due to persistent infection and (4) tran-
scriptional profiles that characterize per-
sistence can be demonstrated in vivo as
recently demonstrated for C. muridarum
(Carey et al., 2013). More challenging
is the identification of diagnostic mark-
ers or transcriptional signature patterns
of persistent viable C. pneumoniae infec-
tion in humans, which may differ from
those observed in experimental models
of persistent infection and vary depend-
ing on the environmental factors in the
host contributing to persistent infection in
different anatomical sites.
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